Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2011-09-29 Director's Dealing
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2011-09-29 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2011, reporting an event related to the sale of shares under an amended investor subscription agreement. It details the closing of a share sale transaction and references a legal opinion attached as an exhibit. The content focuses on a financing event rather than a full financial report, earnings release, or management discussion. The key event is the issuance and sale of shares to investors, which aligns with updates on company fundraising or capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 3152 characters, which is consistent with a typical 8-K filing for such an event, not a full report or announcement of a report publication.
2011-09-29 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-29 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-29 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, company background, recent developments, and risk factors. The presence of terms like 'Prospectus Supplement', 'Registration No.', 'offering price', and detailed offering terms indicates this is a capital raising document. It is not an annual report, earnings release, or management discussion, but specifically a filing related to a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus supplement, not just an announcement of a report.
2011-09-28 English
PRIMARY DOCUMENT
Director's Dealing
2011-09-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.